Responding to the Expansion of the Generic Drug Market
First written in FY2016. 21 of 27 entries say "Restated". Latest entry: 2026-07-15.
3 other companies' latest entry also says "Advanced".
- 2026-07-15AdvancedEarnings presentation
「Phase 2 formulation manufacturing line: scheduled to begin operations from the fiscal year ending May 2027, in line with the contractor's schedule」
The planned start of operations for Phase 2 of the formulation manufacturing line at the Tenth Formulation Building has been made specific in line with the contractor's schedule. - FY2025-H1AdvancedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. Commercial production at Building 10, a new drug product manufacturing facility, began in August 2024. In addition, the Integrated Research Center was completed in March 2024, and the company has begun research and development activities using its equipment.」
Building 10 has progressed from the construction and completion stages to the start of commercial production in August 2024, while the Integrated Research Center also began research and development activities using its equipment after completion. - FY2024-Q3AdvancedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and completed it in December 2023. Given the expected high utilization rate of the production equipment in Phase 1 due to strong orders, and because the company has received further inquiries, it has now begun Phase 2 construction to install production equipment on the 3 floors without equipment, out of the 5 floors available for production equipment in Building 10. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and completed it in March 2024.」
Building 10 has been completed, and Phase 2 construction has begun to install production equipment on the 3 unequipped floors in response to orders. It states that the Integrated Research Center was also completed in March 2024. - FY2024-Q2AdvancedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and completed it in December 2023. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and plans to complete it in March 2024.」
For Building 10, it reports its completion in December 2023, marking progress from the previously stated completion schedule to the specific completion stage. The company continues to plan completion of the Integrated Research Center in March 2024. - FY2024-Q1RestatedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and plans to complete it in December 2023. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and plans to complete it in February 2024.」
It continues to describe the construction plans and expected completion dates for Building 10 and the Integrated Research Center, as in the previous quarter and previous fiscal year, without indicating any new progress. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group is pursuing active sales activities while strengthening its production platform. The company began construction of Building 10, a new drug product manufacturing facility, in September 2022 and plans to complete it in November 2023. In addition, to strengthen its research and development activities, the company began construction of an Integrated Research Center in November 2022 and plans to complete it in February 2024.」
It continues to state that the company is strengthening its production platform and pursuing active sales activities, and continues to describe the construction plans for Building 10 and the Integrated Research Center. - FY2022-Q3RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It states that the company continued strengthening its production platform and pursuing active sales activities, without indicating any new specific initiatives or progress. - FY2022-Q2RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It states that the company continued strengthening its production platform and pursuing active sales activities, without indicating any new specific initiatives or progress. - FY2022-Q1RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
The company continues to strengthen its production platform and pursue active sales activities. No new specific initiatives or progress have been indicated. - FY2021-Q3RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
The company continues to strengthen its production platform and pursue active sales activities. No new specific initiatives or progress have been indicated. - FY2021-Q2RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It states that the company continued strengthening its production platform and pursuing active sales activities, without indicating any new initiatives or specific progress. - FY2021-Q1RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It states that the company continued strengthening its production platform and pursuing active sales activities, without indicating any new initiatives or progress. - FY2020-Q3RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
The company continues to strengthen its production platform and pursue active sales activities. - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It states that the company continued strengthening its production platform and pursuing active sales activities. - FY2020-Q1RestatedAnnual report
「Against this backdrop, the Group pursued active sales activities while strengthening its production platform.」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2019-Q3RestatedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities, and the company constructed the Eighth Finished-Dosage-Form Building, a new manufacturing building for highly pharmacologically active solid dosage forms, which was completed in November 2018.」
It continues to strengthen the production platform and pursue proactive sales activities, and continues to report the November 2018 completion of the Eighth Finished-Dosage-Form Building, as stated in the previous quarter. - FY2019-Q2AdvancedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities, and the company constructed the Eighth Finished-Dosage-Form Building, a new manufacturing building for highly pharmacologically active solid dosage forms, which was completed in November 2018.」
As part of the effort to strengthen the production platform, the Eighth Finished-Dosage-Form Building progressed from being under construction with completion scheduled to a record of completion in November 2018. - FY2019-Q1RestatedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities, and construction of the Eighth Finished-Dosage-Form Building, a new manufacturing building for highly pharmacologically active solid dosage forms, began in October 2017, with completion scheduled for November 2018.」
It continues to present the strengthening of the production platform and proactive sales activities, and describes the Eighth Finished-Dosage-Form Building construction plan as before. - FY2018RestatedAnnual report
「Against this backdrop, our group will promote the timely research and development of new generic products for APIs and finished dosage forms, while expanding production facilities and improving production efficiency, with the aim of increasing earnings.」
It reiterates the policy of increasing earnings through research and development of new generic products, expansion of production facilities, and improved production efficiency. - FY2018-Q3RestatedAnnual report
「Against this backdrop, our group continues to strengthen its production platform and pursue proactive sales activities」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2018-Q2RestatedAnnual report
「Against this backdrop, our group continues to strengthen its production platform and pursue proactive sales activities」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2018-Q1RestatedAnnual report
「Against this backdrop, our group continues to strengthen its production platform and pursue proactive sales activities」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2017RestatedAnnual report
「Against this backdrop, our group will promote the timely research and development of new generic products for APIs and finished dosage forms, while expanding production facilities and improving production efficiency, with the aim of increasing earnings.」
It reiterates the policy of increasing earnings through research and development of new generic products, expansion of production facilities, and improved production efficiency. - FY2017-Q3RestatedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities, and full-scale operations began in the first quarter at the newly constructed Sixth API Building and Third API Packaging Building.」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2017-Q2RestatedAnnual report
「Against this backdrop, our group is strengthening its production platform and pursuing proactive sales activities」
It reiterates the policy of continuing to strengthen the production platform and pursue proactive sales activities. - FY2017-Q1RestatedAnnual report
「Against this backdrop, our group continues to strengthen its production platform and pursue proactive sales activities」
It reiterates the policy of continuing to strengthen the production platform and sales activities. - FY2016First statedAnnual report
「We will promote the timely research and development of new generic products for APIs and finished dosage forms, while expanding production facilities and improving production efficiency, with the aim of increasing earnings.」
A policy of increasing earnings through research and development of new products, expansion of production facilities, and improved production efficiency.